SCHEMBL3996473

SCHEMBL3996473

Clc1cc(N2CCOCC2)cc(Cl)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 1/20 0.56
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 3/20 0.47
LMNA P02545 2/20 0.47
PRKDC P78527 1/20 0.44
MAPK1 P28482 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 3/20 0.42
RAB9A P51151 3/20 0.42
HTT P42858 3/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
LGMN Q99538 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 2/20 0.41
RAF1 P04049 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309176 0.89 MAPT (0.63) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL18595213 0.87 MAPT (0.49) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL3286682 0.87 MAPT (0.57) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL18694117 0.83 HRH3 (0.46) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL24156729 0.83 KMT2A (0.56) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL17820948 0.83 MAPT (0.48) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL12265404 0.83 CYP1A2 (0.56) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL245694 0.82 KMO (0.49) MAPTCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL3998628 0.80 TERT (0.45) MAPTCYP1A2KMT2AKDM4EMAPK1
SCHEMBL19259420 0.79 KMT2A (0.43) MAPTCYP1A2CYP2D6KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP claimed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP claimed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-12637450-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways GLOBAL CANCER TECHNOLOGY INC. (US) 2026-05-26 US disclosed
EP-4673441-A1 LZK INHIBITORS Ureka Bioscienes, Inc. (US) 2026-01-07 EP disclosed
EP-3774783-B1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES INC (US) 2025-06-04 EP disclosed
EP-4069366-B1 ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION INC (US) 2025-03-19 EP disclosed
US-20240327396-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS NEUROPORE THERAPIES, INC. (US) 2024-10-03 US disclosed
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
WO-2024182552-A1 LZK INHIBITORS UEREKA BIOSCIENCES, INC. (US) 2024-09-06 WO disclosed
US-12049462-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways NEUROPORE THERAPIES, INC. (US) 2024-07-30 US disclosed
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167300-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 MAPT 1165/4885CYP1A2 49/4885CYP2D6 120/4885
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP MAPT 4192/4885CYP1A2 3833/4885CYP2D6 4032/4885
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 MAPT 2009/4885CYP1A2 1148/4885CYP2D6 1366/4885
US-12637450-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways PIK3R4, PIK3R1, ATG7 MAPT 3518/4885CYP1A2 3390/4885CYP2D6 3359/4885
US-20240327396-A1 TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS ATG7, ULK1, BECN1 MAPT 1552/4885CYP1A2 3224/4885CYP2D6 3677/4885
US-12049462-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways ATG7, ULK1, BECN1 MAPT 1514/4885CYP1A2 3130/4885CYP2D6 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.